INTERVIEW: Cook MyoSite Eyes Japan As Cell Therapy Trials Progress
This article was originally published in PharmAsia News
In the wake of supportive regulations introduced in 2014, more and more firms in the regenerative medicines space are eyeing Japan as an attractive market. US-based Cook MyoSite is no exception.
You may also be interested in...
Rejection of an RMAT request does not mean necessarily mean the FDA won't grant one. The agency will accept new clinical data to support the application through a “reconsideration” process, industry official says.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.